Fennec Pharmaceuticals is counting on the European Medicines Agency’s rarely used pediatric use marketing authorization (PUMA) pathway to pave its way to winning pan-EU approval for the unique formulation of sodium thiosulfate it is developing to prevent cisplatin-induced hearing loss in children.
The marketing application for the product was recently validated by the EMA, which this month added the drug to its...








